1. Vascular endothelial growth factor C complements the ability of positron emission tomography to predict nodal disease in lung cancer 
Farhood Farjah, MD, MPH, David K. Madtes, MD, Douglas E. Wood, MD, David R. Flum, MD, MPH, Megan E. Zadworny, MHA, Rachel Waworuntu, BS, Billanna Hwang, MPH, Michael S. Mulligan, MD 
The Journal of Thoracic and Cardiovascular Surgery 
Volume 150, Issue 4, Pages e2 (October 2015)
DOI: /j.jtcvs
Copyright © 2015 The American Association for Thoracic Surgery Terms and Conditions

2. Figure 1
Patient accrual and cohort selection. SCLC, Small cell lung cancer; AIS, adenocarcinoma in situ; PET, positron emission tomography; NSCLC, non–small cell lung cancer.
The Journal of Thoracic and Cardiovascular Surgery  , e2DOI: ( /j.jtcvs )
Copyright © 2015 The American Association for Thoracic Surgery Terms and Conditions

3. Figure E1
The Relationship between sextiles of lymphangiogenesis markers and the risk of nodal disease. The x-axis depicts sextiles (S1-S6) of log-transformed plasma levels of vascular endothelial growth factor C (VEGF-C) or vascular endothelial growth factor D (VEGF-D) and the range of values of log-transformed VEGF-C for each sextile in parentheses. The y-axis shows the true prevalence of pathologically confirmed nodal disease for each sextile.
The Journal of Thoracic and Cardiovascular Surgery  , e2DOI: ( /j.jtcvs )
Copyright © 2015 The American Association for Thoracic Surgery Terms and Conditions

4. Predicting nodal disease in lung cancer with and without lymphagiogenesis markers.
The Journal of Thoracic and Cardiovascular Surgery  , e2DOI: ( /j.jtcvs )
Copyright © 2015 The American Association for Thoracic Surgery Terms and Conditions